AIM ImmunoTech (NYSE:AIM), formerly known as Hemispherx Biopharma, is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies. Its core research centers on harnessing and regulating the body’s innate immune response to treat a range of diseases, including viral infections, cancer and immune dysfunction disorders. The company’s lead compounds are designed to activate key signaling pathways, with the ultimate goal of improving patient outcomes in areas that have traditionally been underserved by existing treatments.
The company’s flagship product candidate, rintatolimod (trademarked as Ampligen), is a synthetic double-stranded RNA molecule that acts as a toll-like receptor 3 (TLR3) agonist. Ampligen has been studied in multiple clinical trials for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), certain cancers and antiviral applications, including investigational use against emerging viral pathogens. In addition, AIM ImmunoTech markets Alferon N Injection, an FDA-approved natural alpha interferon indicated for the treatment of refractory genital warts, which provides a commercial foundation while its pipeline advances through regulatory pathways.
Founded in the late 1980s and headquartered in Ocala, Florida, AIM ImmunoTech maintains a research and development presence in both the United States and Canada. The company collaborates with academic institutions, government agencies and contract research organizations to conduct preclinical and clinical studies. Through strategic partnerships, it aims to expand the applicability of its immuno-oncology and antiviral platforms across additional therapeutic indications and geographic regions.
Under the leadership of Chief Executive Officer John N. Scannell, AIM ImmunoTech has strengthened its scientific advisory board and management team to support ongoing clinical development and potential commercialization activities. The board includes experts in immunology, virology and regulatory affairs, reflecting the company’s commitment to advancing novel immune-based therapies. As it progresses through pivotal trials, AIM ImmunoTech continues to position itself as a specialist in the field of innate immune activation.
